ORIGINAL ARTICLES: PDF OnlyPerinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanomaCascinelli, Natale; Clemente, Caudio; Bufalino, Rosaria; Baldini, Maria; Mascheroni, Luigi; Zurrida, Stefano; Mihm, Martin C JrAuthor Information Division of Surgical Oncology B, National Cancer Institute, Via G. Venezian 1, 20133 Milan, Italy. Tel: ( + 39)2 2663992/26680626; Fax: ( + 39)2 26680636. (N. Cascinelli, M. Baldini, L. Mascheroni, S. Zurrida); Division of Anatomic Pathology and Cytology, Nations Cancer Institute, Milan, Italy (C. Clemente); WHO Melanoma Programme (R. Bufalino); Division of Dermatopathology, Massachusetts General Hospital, Boston, MA, USA. (M.C. Mihm Jr) Melanoma Research: November 1993 - Volume 3 - Issue 6 - p 471-476 Buy Abstract The potential therapeutic efficacy of TP5 in patients with cutaneous and subcutaneous metastases of melanoma was tested in a double-blind study comparing the drug and placebo injected perinodularly. Of the 47 nodules present in the 16 patients treated with TP5, 24 showed a measurable response, whereas only one out of 15 nodules in patients treated with a placebo showed a minor response (P = 0.02). In two patients treated with TP5 a response of two nodules not perinodularly injected was also observed. Sclerosis, CD45RO+ cells and MIB 1− cells were more frequently observed in nodules treated with TP5 than with placebo. (P = 8 ± 10−4; 0.03 and 0.01, respectively). Evaluating the trends of these findings in nodules treated with placebo; with TP5-treated, non-responding nodules; or with TP5-treated, responding, a positive trend was observed for sclerosis and CD45RO+ cells (P = 5 ± 10−4 and 2 ± 10−3, respectively) and a negative one for MIB 1 cells (P = 2 ± 10−3). These preliminary data suggest that lymphoid cells associated with nodules regression are activated large lymphocytes (CD45RO+ and CD3−). Sclerosis might be Interpreted as the final morphologic event, and reduction of proliferative activity (MIB 1- cells) as the conseqence of cytolytic action. © Lippincott-Raven Publishers.